Amgen Inc. (NASDAQ:AMGN) has kicked off two crucial phase three trials for MariTide, its investigational weight loss injection. This move marks a significant step in the company’s pursuit to break into the growing market for obesity drugs.
What Happened: The MARITIME program, the drug’s phase three development program, is advancing remarkably well, said Dr. Jay Bradner, Amgen’s Executive Vice President of Research and Development at the 45th Annual TDCowen Healthcare Conference on Wednesday, as per CNBC. MariTide, a monthly injection, is anticipated to rival the existing weekly weight loss injectables from Novo Nordisk‘s (NYSE:NVO) Ozempic and Wegovy and Eli Lilly‘s (NYSE:LLY) Zepbound. These medications belong to a class called GLP-1s, which mimic specific gut hormones to regulate appetite and blood sugar levels.
The initial trial in …
